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Introduction 
The usefulness of gene therapies is largely 
dependent on the transfection efficiency of the therapy. 
Since gene therapy can treat some types of cancer, 
infectious diseases like AIDS, and several 
neurodegenerative diseases [2], there is a great need for 
effective carriers. Many carriers have been developed 
which can, to varying extents, deliver genes to several 
cell types. However, gene size limits, sustained 
expression [3], particle size, and net complex charge 
make delivery of therapies challenging [4, 5]. 
Transfection efficiency, or the ability to deliver chosen 
nucleic acids to cells and produce modified cells [6], 
  
Figure 1. TEM of a Non-viral 
Particle for Drug Delivery [1] 
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must be maximized while minimizing immune response and damage to the host for a therapy to 
be clinically relevant [7].  
Gene delivery vehicles such as viral vectors can 
cause undesirable immune responses and be toxic. Non-
viral systems hold more promise due to lower 
immunogenicity.  Using liposomes, many formulations 
have been successful at entering the cell. Still, delivery 
systems are limited by their ability to succeed with 
endosomal escape. The carriers are frequently captured 
and destroyed by endosomes in the cytoplasm, reducing 
transfection efficiency [8]. Additionally, common non-viral systems such as covalent 
polyethyleneimine (PEI) conjugation are limited by cytotoxicity [9], and calcium phosphate 
models are limited by the size of the genetic material [10]. Complexes composed of liposomes, 
polycationic polymers, and DNA (LPD) have shown promise for a variety of applications, 
including cancer vaccines [11-13], peptide delivery to antigen-presenting cells[14], and other 
therapy possibilities. LPD Complexes are stable after storage for several months [15], are suitable 
for systemic therapy for intravenous delivery [16], and are modifiable for targeting [13, 17]. 
Additionally, DNA has been used effectively as a 
therapeutic tool when combined with polycationic 
polymers alone. Degradable polymers can act as the 
polycationic polymer carrier [18], and charge ratio can be 
used to target delivery to specific organs and cell types 
[19]. Our project intends to overcome the challenge of 
endosomal escape by developing a polycationic polymer. 
A series of polymers were designed and synthesized. We 
have demonstrated that we can use a diamine to cure an 
epoxy-PEG (Polyethylene Glycol), as well as other reagents. In acidic environments, such as the 
interior of the endosome, the polymers degrade rapidly, and the byproducts increase the osmotic 
pressure within the endosome [20]. This increase caused the endosome to swell and burst, 
effectively allowing for endosomal escape. The new polymer was complexed to negatively 
charged DNA. Once the DNA has complexed to the novel polymer, a polar lipid was wrapped 
around the particle, allowing for entrance through the cell membrane (Figure 1).  
Qualitative indicators of transfection were 
shown using a plasmid that encodes for Green 
Fluorescent Protein (GFP), and quantitative 
comparisons were performed using a plasmid that 
encodes for Firefly luciferase. This ongoing project 
works to end the search for a tunable and 
biocompatible carrier that delivers to targeted cells, 
succeeds with endosomal escape, and protects the genetic content, as well as adequately 
characterize the delivery vehicle.  
  
Figure 2. 2-[(2-
aminoethyl)disulfanyl]ethan-1-
amine hydrochloride structure  
(152.29 g/mol) 
 
 
Figure 3. Poly(ethylene glycol) 
diglycidyl ether (MW by #: 500 
g/mol) 
 
 
Figure 4. Polymer A Molecular 
Structure (652 g/mol) 
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Materials and Methods  
Polymer Synthesis: An acid-sensitive polymer 
was synthesized for use in developing a particle 
protocol and for particle characterization. A 
diepoxy was cured with a diamine using 4-
(Dimethylamino)pyridine (DMAP from Sigma-
Aldrich, St. Louis, MO) as a catalyst. 2-[(2-aminoethyl)disulfanyl]ethan-1-amine hydrochloride 
(Figure 2; from Enamine,  Kiev, Ukraine) was dissolved in methanol with DMAP, and the solution 
was reacted with poly(ethylene glycol) diglycidyl ether (Figure 3, from Sigma-Aldrich, St. Louis, 
MO) at a 1:1 ratio while stirring at 50° C under nitrogen for 24 hours. The solvent was removed 
using rotary evaporation, and the polymer was purified using hexanes (Figure 4 shows expected 
structure). The product was characterized using nuclear magnetic resonance spectroscopy (NMR), 
and the new structure was named Polymer A. 
A monoepoxy chemical with a structure 
similar to PEG and ending in a methyl group, 2-((2-
(2-(2-
Methoxyethoxy)ethoxy)ethoxy)methyl)oxirane 
(Figure 5; reagent from Sigma-Aldrich), was 
reacted at a 2:1 ratio with 2-[(2-
aminoethyl)disulfanyl]ethan-1-amine 
hydrochloride to yield Polymer B (Figure 6). The 
reaction was allowed to continue for 24 hours in 2 mg/mL sodium borohydride (from Sigma-
Aldrich) and 0.6 M NaOH (Thermo Fisher Scientific, Waltham, MA) in methanol while stirring 
at 50° C under nitrogen for 24 hours, and the solvent was removed using rotary evaporation. The 
product was characterized using NMR. 
A simple diepoxy connected by a short carbon chain, 
1,2,7,8 diepoxyoctane (Figure 7; reagent from Sigma-
Aldrich), was reacted at a 1:1 ratio with 2-[(2-
aminoethyl)disulfanyl]ethan-1-amine hydrochloride to yield 
Polymer C (Figure 8). The reaction was allowed to continue 
for 24 hours in 2 mg/mL sodium borohydride and 0.6 M 
NaOH in methanol while stirring at 50° C under nitrogen for 
24 hours, and the solvent was removed using rotary 
evaporation. The product was characterized using NMR.  
Polar Liposome Production: 
Liposomes were made from DOTAP 
(Avanti Polar Lipids, Alabaster, 
Alabama) and Cholesterol (Sigma-
Aldrich, St. Louis, MO) using a 1:1 
 
Figure 5. 2-((2-(2-(2-
Methoxyethoxy)ethoxy)ethoxy)methyl)
oxirane (MW 220 g/mol) 
 
Figure 6. Polymer B Intended 
Structure (592.8 g/mol) 
 
 
Figure 7. 1,2,7,8 
diepoxyoctane structure 
 
 
Figure 8. Molecular Structure of Polymer C 
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molar ratio. They were made using thin film 
hydration (R-215 Rotavapor, BÜCHI, New 
Castle, DE), and extrusion (Masterflex 
peristaltic pump model 77800-60, Cole-Parmer, 
Vernon Hills, IL) with 100 nanometer filters 
controlled for  the size of the liposomes.  
LPD complexing: Plasmid DNA (pDNA 
expressing GFP from InvivoGen, San Diego, 
California) was placed in solution in molecular 
grade water, and the polyacetal was placed in a 
second Eppendorf tube. Particle stocks were 
made by mixing the pDNA with the polyacetal 
solution at N/P ratios of 1:1, 3:1, and 5:1. The 
solution was allowed to shake for ten minutes, 
and liposomes were added at low, medium, and high mass ratios to the polymer. Polymer particles 
were made in the same manner without the addition of liposomes.  
Cytotoxicity/ Cell Proliferation: Lactate 
dehydrogenase assay was conducted at 36 
hours per manufacturer’s protocol (Pierce 
from Thermo Fisher Scientific, Waltham, 
MA) to reveal if cells grow well with the 
particles, indicating if the particles are 
suitable for in vivo applications. MTT 
assays were conducted at 36 hours using 0.6 
mg/mL Thiazolyl Blue Tetrazolium 
Bromide in complete media to determine 
cell viability and proliferation with particles 
present. PEI was used in assays for 
comparison.  
Qualitative Gene Expression: Gene Expression was verified using fluorescent microscopy to 
visualize the reporter protein GFP in NIH 3T3 fibroblast cells and RAW macrophages (ATCC, 
Manassas, VA). Cells were plated in a 96 well plated at a concentration of 1,500 cells per well. 
When they reached 70% confluency, media was removed and replaced by particle solutions 
suspended in DMEM Complete Media (Corning, Corning, NY). Expression was captured after 36 
hours of incubation.  
 
Figure 9. Polymer A NMR Spectrum 
 
Figure 10. Polymer B NMR Spectrum 
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LUC Plasmid production: Plasmid 
containing luciferase gene (pLenti 
CMV Puro LUC (w168-1) from 
AddGene, Cambridge, MA) was 
transformed into competent bacteria, 
cultured overnight, and purified using 
a MaxiPrep Kit (Quiagen, Hilden, 
Germany). The sample concentration 
was found using NanoDrop (Thermo 
Fisher Scientific, Waltham, MA), and 
the plasmid was verified using 
restriction enzyme digest and gel 
electrophoreses.  
Quantify Gene Expression:  Gene 
expression was compared with 
varying particle concentrations and 
charge ratios. Fibroblast cells were 
transfected with LUC pDNA particles 
for 36 hours. ATP and Luciferin were 
added, and luminescence was read on a plate reader (Molecular Devices Spectramax M5, 
Sunnyvale, California). PEI was used as a positive control. 
Results/ Discussion 
Polymer Synthesis: NMR 
confirmed the structure of 
Polymer A (Figure 9). 
NMR analysis revealed that 
Polymer B was simply a 
mixture of the reagents, and 
the synthesis did not occur 
as expected (Figure 10). 
Polymer C was 
characterized via NMR, but 
the findings were 
inconclusive. Peaks appear 
both in regions expected of 
the reagents and for the 
structure of the expected 
product (Figure 11). 
Cytotoxicity/ Cell Proliferation of LPD Complexes: Figure 12 shows that the LPD complexes 
using Polymer A allowed cell proliferation until very high concentrations, suggesting 
biocompatibility.  
 
 
Figure 11. Polymer C NMR Spectrum 
 
 
Figure 12. Cell Viability and Proliferation Assay (MTT) of 
LPD Particles with NIH 3T3 Fibroblast Cells: Data presented 
as average +/- standard deviation (n=3) 
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Qualitative Gene Expression of LPD 
Complexes: Figures 13 (left) shows a light 
microscopy image of a representative region of 
GFP transfected cells, and Figure 13 (right) 
shows green light indicative of green 
fluorescent protein expression using 
epiflourescent microscopy. While transfection 
was shown for many concentrations and charge 
ratios, the expression was inconsistent. Lipid 
was removed from the formulation for further 
tuning.  
Cytotoxicity/ Cell Proliferation of LPD 
Complexes: Figure 14 shows the LDH assay 
results of polymer/plasmid complexes. Very 
small amount of cell death was found when pDNA mass surpassed 1 µg, showing minimal 
cytotoxicity. Higher concentrations of particles resulted in greater cell death. Figure 15 shows the 
MTT results for Polymer A. Polymer A allowed for greater proliferation than PEI across the board, 
preferable by an order of magnitude. Decreasing n:p ratio (and thus polymer mass for a given 
amount of plasmid) resulted in greater proliferation for nearly all groups. 
 
 
Figure 13. Light and Epifluorescent 
Microscopy of NIH 3T3 Fibroblasts 
Transfected with GFP from LPD 
Complexes (10x magnification) 
 
 
Figure 14. LDH Cytotoxicity Assay of Polymer/Plasmid 
Particles with NIH 3T3 Fibroblast Cells  
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Qualitative Gene Expression of 
Polymer A/pDNA Complex: 
Transfection with Polymer A 
complexed to plasmid resulted in 
brighter expression of GFP 
(Figure 16) in a more consistent 
way than the LPD complexes.  
Quantified Gene Expression: 
Quantitative analysis of 
transfection using the LUC-
encoding plasmid (Figure 17) 
resulted in very low levels of 
expression at all concentrations and N:P (nitrogen to phosphate) ratios of Polymer A (Figure 18). 
However, only one positive control showed bioluminescence. As such, the protocol for the assay 
needed to be developed further to allow observation of transfection. The lack of strong, consistent 
expression in the positive controls suggested that the assay could have a problem. While working 
 
Figure 15. Cell Viability and Proliferation Assay (MTT) of Polymer/Plasmid Particles with 
NIH 3T3 Fibroblast Cells  
 
 
Figure 16. Light (Left) and Epiflourescent (Right) 
Microscopy of NIH 3T3 Fibroblasts Transfected with 
GFP from Polymer/Plasmid Complexes (10x 
magnification) 
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on this assay, a collaborator used her lab’s resources and found no expression from Polymer A 
complexes, especially relative to the positive control (Figure 19). 
Conclusions 
Overall, a series of polymers 
were synthesized, and structure was 
confirmed for Polymer A, which was 
shown to be less toxic than PEI. 
Complexes made of the polycationic 
polymer and plasmid DNA were 
qualitatively shown to transfect 
fibroblast cells. The initial 
quantitative expression assay 
(luciferin assay) yielded inconclusive  
Figure 18. Bioluminescent Expression as an 
Indicator of Luciferase Concentration 
 
 
 
Figure 17. Gel Electrophoresis of Firefly LUC pDNA and Manufacturer’s Digest 
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data, and the luciferase assay was repeated by a 
collaborator. The new data supported the finding 
that Polymer A and pDNA complexes resulted in 
little to no transfection compared to positive 
controls. While qualitative transfection was shown 
with GFP pDNA, quantitative comparison of 
concentration and charge ratio was not possible 
due to lack of transfecting ability throughout. The 
lack of transfection in contrast with the GFP 
plasmid transfection could be due to different sizes 
of plasmids, charges interacting differently with 
the Firefly LUC plasmid, or other unexplored 
variables. Another likely issue was the size of the 
plasmids. The LUC plasmid had nearly an order of 
magnitude greater base pairs relative to the GFP 
plasmid, making the attachment and stabilization 
incomparable. Ideally, a quantitative assay using 
flow cytometry and GFP plasmid could be used.  
The second polymer, Polymer B, could not be synthesized as planned. Polymer C may have 
been made, but further characterization and purification is necessary before it can be used.  
 
 
Future Directions: To characterize the product from the reaction for Polymer C, Thin Layer 
Chromatography will be used to compare the polarity to the reagents’ polarities. Then, column 
chromatography using silica gel will be used to filter the product by polarity to separate materials. 
Once structure is confirmed and the product is purified, biocompatibility experiments will be 
repeated, and transfection will be quantified using a luciferin assay to help determine the most 
effective formulation.  
 
 
 
 
 
 
 
 
 
 
Figure 19. Bioluminescent Expression 
from Collaborator’s Luciferase Assay: 
Bioluminescence measured as Relative 
Luminescence Unit (RLU) and Data 
presented as average +/- standard 
deviation (n=3) 
 
 
Graham Collins 720332548 GCCOLLIN@live.unc.edu      Senior Thesis  
 
 
References 
[1] Y. Tan, M. Whitmore, S. Li, P. Frederik, L. Huang, LPD Nanoparticles-Novel Nonviral Vector for 
Efficient Gene Delivery, in: J.R. Morgan (Ed.) Gene Therapy Protocols, Springer New York, Totowa, NJ, 
2002, pp. 73-81. 
[2] N. Cartier, S. Hacein-Bey-Abina, C.C. Bartholomae, G. Veres, M. Schmidt, I. Kutschera, M. Vidaud, 
U. Abel, L. Dal-Cortivo, L. Caccavelli, N. Mahlaoui, V. Kiermer, D. Mittelstaedt, C. Bellesme, N. 
Lahlou, F. Lefrere, S. Blanche, M. Audit, E. Payen, P. Leboulch, B. l'Homme, P. Bougneres, C. Von 
Kalle, A. Fischer, M. Cavazzana-Calvo, P. Aubourg, Hematopoietic stem cell gene therapy with a 
lentiviral vector in X-linked adrenoleukodystrophy, Science, 326 (2009) 818-823. 
[3] I.M. Verma, N. Somia, Gene therapy -- promises, problems and prospects, Nature, 389 (1997) 239-
242. 
[4] H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, D.G. Anderson, Non-viral vectors for 
gene-based therapy, Nature reviews. Genetics, 15 (2014) 541-555. 
[5] S. Li, L. Huang, Nonviral gene therapy: promises and challenges, Gene therapy, 7 (2000) 31-34. 
[6] T.K. Kim, J.H. Eberwine, Mammalian cell transfection: the present and the future, Analytical and 
bioanalytical chemistry, 397 (2010) 3173-3178. 
[7] M. Ramamoorth, A. Narvekar, Non viral vectors in gene therapy- an overview, Journal of clinical and 
diagnostic research : JCDR, 9 (2015) GE01-06. 
[8] S. Guo, L. Huang, Nanoparticles escaping RES and endosome: challenges for siRNA delivery for 
cancer therapy, J. Nanomaterials, 2011 (2011) 1-12. 
[9] S.M. Moghimi, P. Symonds, J.C. Murray, A.C. Hunter, G. Debska, A. Szewczyk, A two-stage 
poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy, Molecular therapy : the 
journal of the American Society of Gene Therapy, 11 (2005) 990-995. 
[10] Y. Zhang, A. Satterlee, L. Huang, In Vivo Gene Delivery by Nonviral Vectors: Overcoming 
Hurdles&quest, Molecular Therapy, 20 (2012) 1298-1304. 
[11] Z. Cui, L. Huang, Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-
based vaccines: therapeutic effect against cervical cancer, Cancer Immunology, Immunotherapy, 54 
(2005) 1180-1190. 
[12] M. Whitmore, S. Li, L. Huang, LPD lipopolyplex initiates a potent cytokine response and inhibits 
tumor growth, Gene therapy, 6 (1999) 1867-1875. 
[13] Y. Wang, H.-h. Su, Y. Yang, Y. Hu, L. Zhang, P. Blancafort, L. Huang, Systemic delivery of 
modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy, 
Molecular Therapy, 21 (2013) 358-367. 
[14] J. Dileo, R. Banerjee, M. Whitmore, J.V. Nayak, L.D. Falo, L. Huang, Lipid–protamine–DNA-
mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses, 
Molecular Therapy, 7 (2003) 640-648. 
[15] B. Li, S. Li, Y. Tan, D.B. Stolz, S.C. Watkins, L.H. Block, L. Huang, Lyophilization of cationic 
lipid–protamine–DNA (LPD) complexes, Journal of pharmaceutical sciences, 89 (2000) 355-364. 
[16] S. Li, M. Rizzo, S. Bhattacharya, L. Huang, Characterization of cationic lipid-protamine-DNA 
(LPD) complexes for intravenous gene delivery, Gene therapy, 5 (1998) 930-937. 
[17] S.D. LI, L. Huang, Surface‐Modified LPD Nanoparticles for Tumor Targeting, Annals of the New 
York Academy of Sciences, 1082 (2006) 1-8. 
[18] Y. Zhang, M. Zheng, T. Kissel, S. Agarwal, Design and biophysical characterization of 
bioresponsive degradable poly (dimethylaminoethyl methacrylate) based polymers for in vitro DNA 
transfection, Biomacromolecules, 13 (2012) 313-322. 
[19] L.M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai, K.C. Reuter, M. Meng, D. Fritz, F. Vascotto, 
H. Hefesha, C. Grunwitz, M. Vormehr, Y. Husemann, A. Selmi, A.N. Kuhn, J. Buck, E. Derhovanessian, 
R. Rae, S. Attig, J. Diekmann, R.A. Jabulowsky, S. Heesch, J. Hassel, P. Langguth, S. Grabbe, C. Huber, 
Graham Collins 720332548 GCCOLLIN@live.unc.edu      Senior Thesis  
 
O. Tureci, U. Sahin, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer 
immunotherapy, Nature, 534 (2016) 396-401. 
[20] Y.J. Kwon, Before and after Endosomal Escape: Roles of Stimuli-Converting siRNA/Polymer 
Interactions in Determining Gene Silencing Efficiency, Accounts of Chemical Research, 45 (2012) 1077-
1088. 
 
